Abstract
Ivabradine inhibits hyperpolarization-activated cyclic nucleotide-gated channels in the sinus node, thereby reducing heart rate, and heart rate reduction improves regional myocardial blood flow and contractile function in ischemic myocardium. Accordingly, ivabradine reduces anginal symptoms in patients with stable coronary artery disease but does not improve their clinical outcome. Heart rate reduction with ivabradine in patients with symptomatic heart failure reduces symptoms, attenuates remodeling, and improves clinical outcome. In pigs and mice, ivabradine reduces infarct size from myocardial ischemia/reperfusion, even when heart rate reduction is abrogated by atrial pacing. Improved viability is also observed in isolated ventricular cardiomyocytes subjected to simulated ischemia/reperfusion. These beneficial effects are attributed to reduced reactive oxygen species formation from the mitochondria. There is also evidence for a heart rate-independent benefit from ivabradine in the vasculature of mice and humans, and in left ventricular contractile function of pigs. Finally, in mice, ivabradine also has anti-aging potential.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
